Related Experiment Video

Updated: Jun 23, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents

A Ravaud1

  • 1Department of Medical Oncology and Radiotherapy, Hôpital Saint-Andre, University Hospital, Bordeaux and Université Bordeaux, 2 Victor Segalen, Bordeaux, France. alain.ravaud@chu-bordeaux.fr

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|May 12, 2009
PubMed
Abstract

Insights

Maintaining optimal doses of targeted therapy for metastatic renal cell carcinoma (mRCC) improves survival. Prompt management of adverse events (AEs) ensures treatment benefit and quality of life for mRCC patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Nephrology

Background:

  • Targeted agents are increasingly used for metastatic renal cell carcinoma (mRCC).
  • These therapies present unique adverse events (AEs) requiring prompt management.
  • Effective AE management is crucial for maintaining treatment efficacy and patient quality of life.

Purpose of the Study:

  • To emphasize the importance of maintaining patients on optimal targeted therapy doses in mRCC.
  • To review the safety profiles of targeted agents used in mRCC.
  • To present strategies for managing AEs associated with targeted agents in mRCC.

Main Methods:

  • Review of safety profiles for targeted agents in mRCC.
  • Discussion of strategies for managing treatment-related adverse events.
  • Emphasis on dose optimization for maximizing therapeutic benefit.

Main Results:

  • Higher exposure to targeted agents correlates with improved overall survival in mRCC.
  • Proactive AE management, including patient education and risk assessment, improves compliance.
  • Minimizing AE impact allows patients to remain on targeted therapy.

Conclusions:

  • Targeted agents for mRCC have predictable adverse event profiles.
  • Early detection and effective management of AEs improve patient outcomes.
  • Optimizing AE management supports sustained treatment and better clinical results in mRCC.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...